Traveling for Care?
Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.
A Phase 3 clinical trial comparing Ipilimumab to placebo is currently under way at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. The research study is designed to determine whether Ipilimumab is safe and effective for advanced prostate cancer when given after radiation therapy.
Ipilimumab, an investigational drug also known as MDX-010, has been shown to stimulate the body’s own immune system to fight prostate cancer. In previous studies, Ipilimumab was found to be effective in patients with metastatic prostate cancer that was resistant to hormonal therapy and in some cases, to chemotherapy.
Participants will be in the study for an initial 12 weeks. At that time, patients who are deriving benefit from the Ipilimumab may continue on study indefinitely.
To participate you must:
Principal Investigator at Johns Hopkins:
Charles Drake, M.D., Ph.D.
Associate Professor of Medical Oncology, Immunology and Urology
Co-Director, The Johns Hopkins Prostate Cancer Multi-Disciplinary Clinic
To find out if you may be eligible to participate, please contact:
Monica Taylor, RN, BSN
Clinical Trials Research Nurse
Protocol #: NA_00030529
Promise and Progress
The magazine of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
A publication by the Department of Radiation Oncology and Molecular Radiation Sciences of the Johns Hopkins School of Medicine.
Latest News from the Kimmel Cancer Center